SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Natco Pharma to make, sell bio-generics

19 Oct 2011 Evaluate

Drugmaker Natco Pharma has signed a pact with Switzerland-based Chemo Sa Lugano to source and sell bio-generic products in India and other Asian countries. The pact allows Natco to source four monoclonal antibodies (mAbs) from the Mabxience, a unit of Chemo Sa Lugano, and use them for manufacturing and commercialising finished dosages. Of the four products, three are cancer treatment molecules and one is used in the treatment of auto-immune diseases. Monoclonal antibodies is a highly innovative market globally valued at about Rs 17,250 crore ($35 billion) with insignificant presence of generic products. With the product combinations chosen by Natco, the mAb initiative is likely to be completed over a period of 24-36 months.

Natco Pharma Share Price

1118.95 31.25 (2.87%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×